Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database

Leleu, Xavier; Gorsh, Boris; Bessou, Antoine; Paka, Prani; Nascimento, Julie De; Colin, Xavier; Landi, Suzanne N.; Wang, Peter Feng

doi:10.1111/ejh.13976

Cited by 3 publications

(1 citation statement)

References 24 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is the second most common hematological malignancy in many countries [ 2 – 4 ] and has a substantial impact on public health. The specific incidence of MM in China is not clear, but the median age of onset is 57.9–59 years old [ 5 , 6 ], which is far lower than that observed in western countries [ 7 – 9 ]. In recent years, new chemotherapies and immune drugs have greatly improved the remission rate and survival time in MM [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma

Zhou,

Chen,

Gong

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Purpose To evaluate the efficacy of next-generation sequencing (NGS) in minimal-residual-disease (MRD) monitoring in Chinese patients with multiple myeloma (MM). Methods This study analyzed 60 Chinese MM patients. During MRD monitoring in these patients’ post-therapy, clonal immunoglobulin heavy chain (IGH) rearrangements were detected via NGS using LymphoTrack assays. MRD monitoring was performed using NGS or next-generation flow cytometry (NGF), and the results were compared. Additionally, the sensitivity and reproducibility of the NGS method were assessed. Results The MRD detection range of the NGS method was 10–6–10–1, which suggested good linearity, with a Pearson correlation coefficient of 0.985 and a limit of detection of 10–6. Intra- and inter-assay reproducibility analyses showed that NGS exhibited 100% reproducibility with low variability in clonal cells. At diagnosis, unique clones were found in 42 patients (70.0%) with clonal IGH rearrangements, which were used as clonality markers for MRD monitoring post-therapy. Comparison of NGS and NGF for MRD monitoring showed 79.1% concordance. No samples that tested MRD-positive via NGF were found negative via NGS, indicating the higher sensitivity of NGS. MRD could be detected using NGS in 6 of 7 samples before autologous hematopoietic stem-cell transplantation, and 5 of them tested negative post-transplantation. In contrast, the NGF method could detect MRD in only 1 sample pre-transplantation. Conclusion Compared with NGF, NGS exhibits higher sensitivity and reproducibility in MRD detection and can be an effective strategy for MRD monitoring in Chinese MM patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma

Zhou,

Chen,

Gong

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study

Ruotsalainen,

Lehmus,

Putkonen

et al. 2023

Ann Hematol

View full text Add to dashboard Cite

This study aimed to determine the incidence and prevalence of multiple myeloma (MM) in Finland in 2015–2019, to characterize adult patients newly diagnosed with MM, and to follow-up their overall survival (OS) and treatment patterns until the end of 2020. We sourced the data on inpatient and outpatient diagnoses, outpatient medication use, and date of death from comprehensive, nationwide registers. We identified 2037 incident patients with MM in 2015–2019. On average, the annual crude incidence was 8.8 and the age-standardized incidence (World Standard Population) was 3.3 per 100,000. The crude prevalence at the end of 2019 was 32.7 cases per 100,000 inhabitants ≥ 18 years of age. Median age of the patients at first diagnosis (index date) was 71 years, and 48% were female, the median follow-up being 2.4 years. The median OS was estimated at 4.5 years. The proportion of the patients receiving autologous stem cell transplantation (ASCT) within one year since the index date was 24%, with little variation across study years. Conversely, the proportion of all patients receiving lenalidomide within one year since the index date increased from 27 to 48% overall, and from 39 to 81% among ASCT recipients. The estimated median relapse-free survival after ASCT was 2.9 years. Information on in-hospital MM medication administrations was available for a subset of the study cohort. In this subset, 85.8% of the patients received immunomodulatory drugs and/or proteasome inhibitors within the first year after the index date.

show abstract

Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real‐world setting: The ALFA study

Roussel,

Texier,

Nael

et al. 2024

European J of Haematology

View full text Add to dashboard Cite

ObjectivesThe aim of this noninterventional, retrospective ALFA study was to describe belantamab mafodotin effectiveness and safety in patients with relapsed/refractory multiple myeloma in a real‐world setting in France.MethodsResponse rate, progression‐free survival (PFS), overall survival (OS), and safety were assessed.ResultsAmong the 184 patients initiating belantamab mafodotin treatment, the overall response rate was 32.7% (≥very good partial response [VGPR] 20.4%, partial response [PR] 12.3%). The median PFS (mPFS) was 2.4 months (95% confidence interval [CI]: 1.9, 3.3), and median OS (mOS) was 8.8 months (95% CI: 6.3, 11.6). According to best response, mPFS was 20.6 months (95% CI: 12.1, not reached [NR]) in patients with ≥VGPR and 7.1 months (95% CI: 4.6, 9.4) in patients with PR; mOS was NR in patients with ≥VGPR and 17.5 months (95% CI: 7.7, NR) in patients with PR. For both OS and PFS, no differences were found in subgroups of interest. The adverse events (AEs) reported in 159 patients (86.4%) were mostly ocular AEs.ConclusionsALFA, the largest real‐world cohort conducted so far, confirms the results of belantamab mafodotin as reported in the DREAMM‐2 clinical trial. The clinical benefit is significant as long as the patient is a responder.

show abstract

Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database

Cited by 3 publications

References 24 publications

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma

Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study

Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real‐world setting: The ALFA study

Contact Info

Product

Resources

About